CCO Oncology Podcast

Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Episode Summary

In this podcast episode, listen to Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, discuss key updates and new clinical trial data for gynecologic cancers presented at the ESMO 2023 Congress.

Episode Notes

In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including:

• Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer
• Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer
• First results from a phase II biomarker-directed platform study with assigned treatments for patients with measurable persistent or recurrent platinum-resistant epithelial ovarian cancer based on tumor-specific molecular alterations (ENGOT-GYN/GOG-3051/BOUQUET)
• Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
• An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE)
• Primary results from the global, randomized phase III BEATcc trial of atezolizumab plus platinum-based chemotherapy + bevacizumab as frontline treatment in patients with persistent, recurrent, or metastatic cervical cancer
• Interim analysis results from the global, randomized, open-label phase III innovaTV 301 study of tisotumab vedotin vs investigator’s choice of chemotherapy in second-line or third-line recurrent/metastatic cervical cancer

Presenters:

Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Laboratories RESHAPE 
Université Claude Bernard Lyon Est
Lyon, France

This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. 

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq